Can Cannabis Help Your Gut?
When Joe Silverman developed Crohn’s disease at age 21, the symptoms started out mild. While the sight of blood in his stools initially freaked him out, what really bothered him was the frequent abdominal pain and bloating that occurred as his condition progressed to moderate and then severe. Dietary changes didn’t make a difference, so he began taking prescription oral anti-inflammatory drugs that are often used to treat certain bowel diseases, which alleviated but didn’t eliminate his discomfort. He started using prescription steroid suppositories to cope with flare-ups of the inflammatory bowel disease...
Source: TIME: Health - September 23, 2021 Category: Consumer Health News Authors: Stacey Colino Tags: Uncategorized Source Type: news

Robotic Gastrectomy for Gastric Cancer Does Not Cut Postop Infections
But overall incidence of postoperative complications significantly lower with robotic versus laparoscopic gastrectomy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 22, 2021 Category: Cancer & Oncology Tags: Gastroenterology, Infections, Oncology, Surgery, Journal, Source Type: news

No Drop in Intra-Abdominal Infectious Complications With Robotic Gastrectomy No Drop in Intra-Abdominal Infectious Complications With Robotic Gastrectomy
Robotic gastrectomy failed to reduce intra-abdominal infectious complications compared with standard laparoscopic gastrectomy in a randomized clinical trial of 236 patients with gastric cancer.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 22, 2021 Category: Surgery Tags: General Surgery News Source Type: news

Screening and Treating H. Pylori in Those at High Risk for Gastric Cancer Appears Cost-Effective Screening and Treating H. Pylori in Those at High Risk for Gastric Cancer Appears Cost-Effective
Screening for and treating Helicobacter pylori infection in those at high risk for gastric cancer is cost effective, a new modeling study shows.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - September 14, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

Ramucirumab Shows Survival Benefits with Pleural Mesothelioma
Adding the drug ramucirumab to gemcitabine chemotherapy worked especially well in a recent clinical trial involving second-line treatment for patients with pleural mesothelioma. Ramucirumab, an immunotherapy drug also known by the brand name Cyramza, is a monoclonal antibody that works by targeting and restricting a protein that stimulates blood vessel growth within tumors. Impressive results in the phase II clinical trial moved the drug combination closer to filling the long-standing void for a second-line mesothelioma treatment. The Lancet Oncology recently published results of the study, which was conducted in ...
Source: Asbestos and Mesothelioma News - September 13, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Medial EarlySign signs deal with Roche to develop AI-enabled cancer detection tool
The new initiative will begin with a focus on gastric cancer.   (Source: mobihealthnews)
Source: mobihealthnews - September 13, 2021 Category: Information Technology Source Type: news

I Didn ’t Want to Push My Aunt to Get the Vaccine. Now I Live With Regrets
In normal times, the ICU is a dreadful place. Sickness lingers like a fog. You can feel it, sense it, even hear it—the machinery pumping, the alarms ringing, the nurses scrambling. In pandemic times, the ICU is chilling. Death lives here. Medical staff members wear green biohazard suits, face shields, latex gloves and shoe coverings. Strips of red tape—“ISOLATION,” they read—mark the windows and doors of individual rooms. Behind each is a patient who cannot breathe on their own, kept alive by a ventilation machine that is connected to an invasive tube running down their windpipe and into the l...
Source: TIME: Health - September 12, 2021 Category: Consumer Health News Authors: Ross Dellenger Tags: Uncategorized Source Type: news

New Report Details 9/11 Health Effects on FDNY Firefighters
A recent report from the Fire Department of New York World Trade Center Health Program outlines the 9/11-related health effects firefighters are dealing with 20 years later. Approximately 410,000 first responders spent the days and weeks after 9/11 inhaling toxic materials as they helped save lives from the collapse of the Twin Towers. Almost 3,000 people died on Sept. 11, 2001, but in the 20 years since, another 4,343 survivors have died due to related health effects. FDNY has felt the impact of delayed illness, as well. While 343 FDNY firefighters died on 9/11, another 254 have died since then from 9/11-related dis...
Source: Asbestos and Mesothelioma News - September 9, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Fecal Transplants: a New Treatment for IBD
Linda Ann Sasser has had ulcerative colitis since she was 20, but it wasn’t until May 2019, about 30 years later, that her condition hit a low point: not only did she have a major flare-up of chronic inflammatory bowel disease (IBD), but on top of it, she had Clostridioides difficile (or C. diff), a highly contagious bacterial infection that causes severe diarrhea and inflammation of the colon. “I became really, really sick with bloody diarrhea 30 times a day and chronic stomach pain,” Sasser says. While hospitalized for 12 days, she was given oral steroid medications, which didn’t help, then IV ste...
Source: TIME: Health - September 9, 2021 Category: Consumer Health News Authors: Stacey Colino Tags: Uncategorized Disease feature Source Type: news

New Blood Test Can Help Detect Early Stomach Cancer New Blood Test Can Help Detect Early Stomach Cancer
A blood test based on microRNA can help detect early-stage stomach cancer noninvasively, according to new research.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - September 8, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

DR ELLIE CANNON: I can't stop worrying that cancer runs in my family - and I'll be next
Cancer isn't one disease, it's many. So, for example, the causes and characteristics of bladder cancer are quite distinct and not connected to those of stomach cancer or other cancers, says DR ELLIE. (Source: the Mail online | Health)
Source: the Mail online | Health - September 4, 2021 Category: Consumer Health News Source Type: news

Screening for H. pylori in patients at high risk of gastric cancer appears to be cost saving in the USA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 1, 2021 Category: Drugs & Pharmacology Source Type: news

A New AI Technology Might Help Detect Gastric Cancer
Each year, one million patients around the globe are diagnosed with stomach cancer. Can a new cancer-detecting AI help save lives? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 27, 2021 Category: Pharmaceuticals Authors: Laken Brooks, Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news

Cancer: The common health complaint that can signal you're at risk of the deadly disease
HEARTBURN is a burning feeling in the chest caused by stomach acid travelling up towards the throat. In some instances, the condition could signal cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - August 25, 2021 Category: Consumer Health News Source Type: news

CT radiomic features predict gastric cancer chemotherapy response
A CT-based radiomics model helped clinicians predict response to neoadjuvan...Read more on AuntMinnie.comRelated Reading: AI predicts metastasis in gastric cancer patients AI may predict lymph node metastasis in gastric cancer AIUM: Double dose of US contrast helps find gastric lesions Surgery plus RT works best for metastatic gastric cancer ASCO GI: CT unnecessary for staging early gastric cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 19, 2021 Category: Radiology Source Type: news

Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy
Basel, 18 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel, advancing the company's commitment to personalised healthcare through tests that determine which patients are most likely to benefit from specific and targeted therapies. The VENTANA MMR RxDx Panel is the first companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair (MMR), who may be eligible for JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD-1 immunotherapy from GSK. The test evaluates a panel of MMR p...
Source: Roche Media News - August 18, 2021 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy
Basel, 18 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel, advancing the company's commitment to personalised healthcare through tests that determine which patients are most likely to benefit from specific and targeted therapies. The VENTANA MMR RxDx Panel is the first companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair (MMR), who may be eligible for JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD-1 immunotherapy from GSK. The test evaluates a panel of MMR p...
Source: Roche Investor Update - August 18, 2021 Category: Pharmaceuticals Source Type: news

Perioperative SOX Protocol Bests Adjuvant CapOx in Locally Advanced Gastric Cancer Perioperative SOX Protocol Bests Adjuvant CapOx in Locally Advanced Gastric Cancer
In patients who had a D2 gastrectomy, perioperative administration of the oral fluoropyrimidine derivative S-1 and oxaliplatin yielded better outcomes than adjuvant capecitabine and oxaliplatin in a phase 3 trial.Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Disgraced anti-vaxxer 'nurse', 54, who compared medics to Nazis only worked briefly for NHS
Kate Shemirani also ran a clinic injecting clients with Botox and claims to have beaten breast cancer with coffee enemas and injecting her stomach with mistletoe. (Source: the Mail online | Health)
Source: the Mail online | Health - July 26, 2021 Category: Consumer Health News Source Type: news

Biocon eyes market share expansion in developed, emerging markets: Kiran Mazumdar-Shaw
“Trastuzumab (monoclonal antibody used to treat breast and stomach cancers) is another big opportunity we are looking at, not just in the US and Europe, but it is a very large global opportunity with growth potential for us,” Mazumdar-Shaw said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 23, 2021 Category: Pharmaceuticals Source Type: news

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being pr...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cancer symptoms: Five sensations in your body that may be indicative of a growing tumour
CANCER cells accumulating inside of the stomach or stomach lining is more common once a person reaches a certain age; according to Cancer Research UK, 50 percent of cases occur in people aged 75 and over. (Source: Daily Express - Health)
Source: Daily Express - Health - July 1, 2021 Category: Consumer Health News Source Type: news

Blood test for personalized cancer treatment
(Flinders University) A blood test to help guide the treatment of esophageal, stomach and bowel cancers will be evaluated in a new Flinders University trial set to get underway. The trial is thanks to a federal government grant of almost $2 million announced yesterday, with Flinders University awarded funding for three projects, totaling $5.8 million. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 1, 2021 Category: Cancer & Oncology Source Type: news

Metabolites in Plasma Could Serve as Biomarkers for Early Gastric Cancer Metabolites in Plasma Could Serve as Biomarkers for Early Gastric Cancer
Decreased plasma metabolite levels show promise as noninvasive biomarkers for early gastric cancer in high-risk populations, a new study from China suggests.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 30, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

How to lose visceral fat: The simple dietary trick to burn the belly fat
VISCERAL fat is packed between the abdominal organs, such as the stomach, liver and kidneys. This intra-abdominal belly fat, in excess amounts, can increase the risk of diabetes, cardiovascular disease, and cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - June 13, 2021 Category: Consumer Health News Source Type: news

FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas
On January 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma
Hematology / Oncology (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 10, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Male hormones regulate stomach inflammation in mice
NIEHS research shows that male sex hormones are anti-inflammatory and could lead to new treatment strategies for stomach cancer. (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - June 2, 2021 Category: Environmental Health Source Type: news

Liver, Gastric Cancer Disparities Consistent Across Race Liver, Gastric Cancer Disparities Consistent Across Race
A recent analysis of US data clearly highlights the need to step up efforts to help level disparities in gastrointestinal cancer.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 27, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Memorial Sloan Kettering Opening New Mesothelioma Clinical Trial
Memorial Sloan Kettering Cancer Center in New York City will begin recruiting soon for its latest clinical trial involving patients with malignant pleural mesothelioma and the expanded use of immunotherapy. The single-center, phase I study will explore the effectiveness of pembrolizumab in combination with intensity-modulated pleural radiation therapy, known as IMPRINT, in treating unresectable disease. Pembrolizumab, also known by the brand name Keytruda, was approved by the U.S. Food and Drug Administration in 2020 for treatment of a small subset of mesothelioma patients. As a well-known immunotherapy drug, pemb...
Source: Asbestos and Mesothelioma News - May 26, 2021 Category: Environmental Health Authors: Matt Bardsley Source Type: news

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve p...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Male hormones regulate stomach inflammation in mice
NIH research could lead to new treatment strategies for stomach cancer. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - May 14, 2021 Category: American Health Source Type: news

Male hormones regulate stomach inflammation in mice
(NIH/National Institute of Environmental Health Sciences) Scientists at the National Institutes of Health determined that stomach inflammation is regulated differently in male and female mice after finding that androgens, or male sex hormones, play a critical role in preventing inflammation in the stomach. The finding suggests that physicians could consider treating male patients with stomach inflammation differently than female patients with the same condition. The study was published in Gastroenterology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 14, 2021 Category: Cancer & Oncology Source Type: news

Cancer may cause stomach bloating if the tumour is growing in size
CANCER statistics are shocking - one in two people will develop the disease at some point during their lifetime. Thankfully, advances in treatment has increased survival chances by more than half. However, early diagnosis is vital. (Source: Daily Express - Health)
Source: Daily Express - Health - May 13, 2021 Category: Consumer Health News Source Type: news

All gas, no brakes: Testosterone may act as 'brake pedal' on immune response
(West Virginia University) Jonathan Busada, a researcher with the WVU School of Medicine and Cancer Institute, has investigated the role that hormones play in male and female inflammatory responses. In a new study, he found that testosterone may protect against stomach inflammation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 12, 2021 Category: Cancer & Oncology Source Type: news

FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer
VANCOUVER, BC, May 11, 2021 -- (Healthcare Sales & Marketing Network) -- Bold Therapeutics, a clinical-stage biopharmaceutical company, is announcing that the U.S. Food & Drug Administration (FDA) has granted BOLD-100 an Orphan Drug Designation (ODD) in t... Biopharmaceuticals, Oncology, FDA Bold Therapeutics, BOLD-100, ruthenium, Gastric Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 11, 2021 Category: Pharmaceuticals Source Type: news

Stomach bloating may be a tell-tale symptom of a tumour in the reproductive organs
STOMACH bloating that is persistent is one key sign of ovarian cancer; there are three other signs, including urinary symptoms. What toiletry habits should you be taking note of? (Source: Daily Express - Health)
Source: Daily Express - Health - May 7, 2021 Category: Consumer Health News Source Type: news

FDA OKs Upfront Pembro for Advanced HER2+ Gastric Cancer FDA OKs Upfront Pembro for Advanced HER2+ Gastric Cancer
The accelerated approval is for first-line use in combination with other agents for locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 6, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 5, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Merck ’s Keytruda (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) May 5, 2021-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 5, 2021 Category: Drugs & Pharmacology Source Type: news

Gastrectomy for Gastric Cancer Associated With Weight Loss, Diabetes Remission Gastrectomy for Gastric Cancer Associated With Weight Loss, Diabetes Remission
Gastric cancer patients with diabetes who undergo conventional gastrectomy have an increased likelihood of diabetes remission with greater postoperative weight loss, independent of baseline weight, a recent study suggests.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 4, 2021 Category: Surgery Tags: General Surgery News Source Type: news

Mortality Risk Up for Fragmented Care After Complex Cancer Surgery
Mortality higher for patients readmitted to outside hospital rather than index hospital after hepatopancreatobiliary or gastric cancer surgery (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 3, 2021 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Surgery, Journal, Source Type: news

Mortality Risk Up for Fragmented Care After Complex Cancer Surgery
MONDAY, May 3, 2021 -- Travel distance and timing contribute to care fragmentation following hepatopancreatobiliary (HPB) and gastric oncologic operations, according to a study published online April 15 in the Journal of the American College of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 3, 2021 Category: Pharmaceuticals Source Type: news

Humana partially reverses PET/CT policy
Humana will begin covering PET/CT imaging for gastric and esophageal oncologi...Read more on AuntMinnie.comRelated Reading: FDG-PET/CT may increase survival in SCC patients FDG-PET/CT effective for staging in new breast cancer SNMMI provides update on COVID-19 vaccine and PET/CT PET/CT shows link between stress and fatal heart condition Nuclear medicine groups oppose Humana PET/CT policy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 27, 2021 Category: Radiology Source Type: news

Cholestenone shows antibiotic properties against H. pylori
(Shinshu University) Helicobacter pylori, a gram-negative pathogen that has infected half of the world's population is a Group I carcinogen according to the WHO. H. pylori resides in the gastric mucosa causing gastritis, ulcers, gastric cancers and gastric malignant lymphoma. It can be eradicated in most infected people using a combination of three drugs including antibiotics clarithromycin. However drug-resistant H. Pylori is a growing problem and it is expected to develop drugs that exhibit anti-H. pylori activity. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 27, 2021 Category: International Medicine & Public Health Source Type: news

Opdivo Plus Chemotherapy Approved for Treatment of Gastric Cancer
FDA granted Opdivo first approval of immunotherapy for first - line treatment of advanced or metastatic gastric cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 20, 2021 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, FDA Approvals, Source Type: news

Opdivo Plus Chemotherapy Approved for Treatment of Gastric Cancer
TUESDAY, April 20, 2021 -- Opdivo (nivolumab) is now approved for the treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, the U.S. Food and Drug Administration announced Friday. The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 20, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma Regardless of PD-L1 Expression Status
PRINCETON, N.J.--(BUSINESS WIRE)-- April 16, 2021 Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival versus chemotherapy alone in a trial of this patient population1 U.S. Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 16, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves Frontline Immunotherapy for Gastric Cancers FDA Approves Frontline Immunotherapy for Gastric Cancers
The approval marked a first for an immunotherapy in patients with gastric cancers.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 16, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma
Hematology / Oncology (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 16, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news